Adjuvant therapy after FUAS and Follow-up
To consolidate the efficacy of FUAS in the treatment of adenomyosis,
three to six cycles of
gonadotropin-releasing hormone agonist (GnRH-a) were suggested for
patients whose uteri were greater
than 10 weeks of gestation or the length of the uterine cavity were more
than 9 cm. Then mirena was
recommended for patients without fertility requirement when the uterus
volume were suitable15. Accordingly, patients were
included in FUAS group and FUAS+ (combined with GnRH-a/mirena) group
based on the therapeutic regimen.
To evaluate FUAS efficacy, patients were suggested for regular
follow-up. From August 2021 to December 2021, 643 patients completed the
questionnaire either on the spot or by telephone if they could not come
back to our cohort.